drugset / Trial / NCT05769920

Dose Escalation TTHX1114 Ophthalmic Solution

NCT05769920 ↗

Phase 1 Completed 8 enrolled Trefoil Therapeutics, Inc.
Non-randomizedSequentialOpen-labelOther

Summary

Dose escalation 3+3 design with accelerated titration 4 dose levels

Timeline

Start
2022-12-06
Primary completion
2023-04-12
Completion
2023-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TTHX1114 Protein / enzyme biologic 1 unknown Topical

Indications